Additionally, midostaurin has been shown to potentially improve OS and disease-free survival in FLT3-ITD AML patients with chromatin-spliceosome mutations [46], and relapsed/refractory FLT3-mutated AML patients with DNMT3A/NPM1 co-mutations experienced the most positive outcomes when treated with gilteritinib [47]. Here, NPM1 is linked to acute myeloid leukemia.